

# Douglas Yee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4017621/publications.pdf>

Version: 2024-02-01

224  
papers

17,376  
citations

13827

67  
h-index

16127

124  
g-index

228  
all docs

228  
docs citations

228  
times ranked

19862  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1029-1035.	3.0	3
2	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.	7.7	92
3	Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choice. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1588-1595.	1.5	4
4	Disrupting Insulin and IGF Receptor Function in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 555.	1.8	31
5	Recent advances in neoadjuvant therapy for breast cancer. <i>Faculty Reviews</i> , 2021, 10, 2.	1.7	8
6	Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. <i>Breast Cancer</i> , 2021, 28, 618-629.	1.3	20
7	Abstract PS6-05: Impact of body mass index on pathological complete response after neoadjuvant chemotherapy: Results from the I-SPY 2 trial. , 2021, , .		0
8	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	8
9	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
10	The Emerging Role of the Fetal Insulin Receptor in Hormone-refractory Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	0
11	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	3.4	42
12	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	2.3	13
13	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. <i>Nature Communications</i> , 2021, 12, 6428.	5.8	36
14	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
15	Advances in insulin-like growth factor biology and -directed cancer therapeutics. <i>Advances in Cancer Research</i> , 2020, 147, 229-257.	1.9	12
16	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	0.8	69
17	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 676.	3.4	419
18	Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage IIâ€“III Breast Cancer: A Multicenter Value Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1510-1517.	2.3	15

#	ARTICLE	IF	CITATIONS
19	Green Tea Catechin Extract Supplementation Does Not Influence Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast Cancer. <i>Journal of Nutrition</i> , 2019, 149, 619-627.	1.3	20
20	I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 303-310.	0.5	49
21	Role of Insulin-Like Growth Factor Receptors in Cancer Signaling. , 2019, , 283-288.		0
22	40 YEARS OF IGF1: Anti-insulin-like growth factor therapy in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T61-T68.	1.1	19
23	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2018, , 765-785.	0.1	0
24	Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. <i>JCO Precision Oncology</i> , 2018, 2, 1-20.	1.5	30
25	Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. <i>Breast Cancer Research</i> , 2018, 20, 115.	2.2	63
26	Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. <i>Hormones and Cancer</i> , 2018, 9, 371-382.	4.9	14
27	Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1324-1334.	1.9	26
28	Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation. <i>Hormones and Cancer</i> , 2017, 8, 219-229.	4.9	14
29	Type I Insulin-Like Growth Factor Receptor. , 2017, , 823-829.		0
30	IGF 1 and IGF 2. , 2017, , 739-743.		0
31	MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 290-302.	1.9	49
32	Use of dual-energy computed tomography to measure skeletal-wide marrow composition and cancellous bone mineral density. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 428-436.	1.3	28
33	A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 710-718.	0.7	72
34	Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 541-547.	1.1	32
35	Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 2287-2289.	13.9	68
36	Revisiting the IGF-1R as a breast cancer target. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	75

#	ARTICLE	IF	CITATIONS
37	Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. <i>Breast Cancer Research</i> , 2017, 19, 107.	2.2	19
38	Mobile Phone Multilevel and Multimedia Messaging Intervention for Breast Cancer Screening: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2017, 5, e154.	1.8	47
39	Adaptive Randomization of Veliparib+Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	13.9	467
40	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	13.9	301
41	Neoadjuvant as Future for Drug Development in Breast Cancer+Response. <i>Clinical Cancer Research</i> , 2016, 22, 269-269.	3.2	6
42	EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. <i>Endocrine-Related Cancer</i> , 2016, 23, 747-758.	1.6	25
43	<sup>64</sup> Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor. <i>Molecular Pharmaceutics</i> , 2016, 13, 3747-3755.	2.3	13
44	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. <i>Science Advances</i> , 2016, 2, e1601737.	4.7	175
45	Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. <i>Neoplasia</i> , 2016, 18, 100-110.	2.3	14
46	Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. <i>Oncogene</i> , 2016, 35, 4235-4243.	2.6	32
47	Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. <i>Cancer Research</i> , 2016, 76, CT042-CT042.	0.4	13
48	Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL, , 2016, , .		8
49	Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0150564.	1.1	13
50	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2016, , 1-21.	0.1	0
51	Minireview: Were the IGF Signaling Inhibitors All Bad?. <i>Molecular Endocrinology</i> , 2015, 29, 1549-1557.	3.7	72
52	Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. <i>SpringerPlus</i> , 2015, 4, 689.	1.2	26
53	Longitudinal FDG-PET Revealed Regional Functional Heterogeneity of Bone Marrow, Site-Dependent Response to Treatment and Correlation with Hematological Parameters. <i>Journal of Cancer</i> , 2015, 6, 531-537.	1.2	14
54	Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. <i>Vascular Health and Risk Management</i> , 2015, 11, 591.	1.0	29

#	ARTICLE	IF	CITATIONS
55	Spatial and Temporal Fracture Pattern in Breast and Gynecologic Cancer Survivors. <i>Journal of Cancer</i> , 2015, 6, 66-69.	1.2	11
56	Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. <i>SpringerPlus</i> , 2015, 4, 32.	1.2	8
57	CCR 20th Anniversary Commentary: Stayin' Alive—Antiapoptotic Proteins and Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 665-666.	3.2	0
58	A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. <i>Bone</i> , 2015, 73, 90-97.	1.4	27
59	IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S52-S53.	2.0	0
60	A Tale of Two Receptors: Insulin and Insulin-Like Growth Factor Signaling in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 667-669.	3.2	26
61	eIF4E Threshold Levels Differ in Governing Normal and Neoplastic Expansion of Mammary Stem and Luminal Progenitor Cells. <i>Cancer Research</i> , 2015, 75, 687-697.	0.4	12
62	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2911-2915.	3.2	77
63	The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics. <i>Cancer Causes and Control</i> , 2015, 26, 1405-1419.	0.8	38
64	Validation of marrow fat assessment using noninvasive imaging with histologic examination of human bone samples. <i>Bone</i> , 2015, 72, 118-122.	1.4	42
65	Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. <i>Oncogene</i> , 2015, 34, 506-515.	2.6	112
66	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0133152.	1.1	78
67	Insulin-Like Growth Factors, Insulin, and Growth Hormone Signaling in Breast Cancer: Implications for Targeted Therapy. <i>Endocrine Practice</i> , 2014, 20, 1214-1221.	1.1	20
68	IGF-I Regulates Redox Status in Breast Cancer Cells by Activating the Amino Acid Transport Molecule xC <sup>+</sup> . <i>Cancer Research</i> , 2014, 74, 2295-2305.	0.4	43
69	A Dual-Radioisotope Hybrid Whole-Body Micro-Positron Emission Tomography/Computed Tomography System Reveals Functional Heterogeneity and Early Local and Systemic Changes Following Targeted Radiation to the Murine Caudal Skeleton. <i>Calcified Tissue International</i> , 2014, 94, 544-552.	1.5	13
70	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2—Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210
71	Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S184-S185.	2.0	0
72	Arterial elasticity in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9604-9604.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Utilizing RNA-Seq to Define Phytochemical-Induced Alterations in Insulin and IGF-Regulated Transcriptomes. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 189-204.	0.1	0
74	The Influence of Therapeutic Radiation on the Patterns of Bone Remodeling in Ovary-Intact and Ovariectomized Mice. <i>Calcified Tissue International</i> , 2013, 92, 372-384.	1.5	12
75	Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1578-1584.	1.9	73
76	Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 351-360.	1.1	21
77	BMP-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization. <i>Developmental Biology</i> , 2013, 373, 95-106.	0.9	30
78	APOBEC3B is an enzymatic source of mutation in breast cancer. <i>Nature</i> , 2013, 494, 366-370.	13.7	758
79	Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2013, 19, 2817-2823.	3.2	21
80	Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis. <i>PLoS ONE</i> , 2013, 8, e68742.	1.1	12
81	Type I Insulin-Like Growth Factor Receptor. , 2013, , 1-7.		0
82	Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment. <i>Cancer Research</i> , 2012, 72, 3372-3380.	0.4	99
83	Should diabetic women with breast cancer have their own intervention studies?. <i>Endocrine-Related Cancer</i> , 2012, 19, C13-C17.	1.6	0
84	Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?. <i>Journal of the National Cancer Institute</i> , 2012, 104, 975-981.	3.0	172
85	Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development. <i>Journal of Clinical Oncology</i> , 2012, 30, 4584-4586.	0.8	13
86	DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 4-aminobiphenyl are infrequently detected in human mammary tissue by liquid chromatography/tandem mass spectrometry. <i>Carcinogenesis</i> , 2012, 33, 124-130.	1.3	41
87	Omission of radiation therapy after breast-conserving surgery in the United States. <i>Cancer</i> , 2012, 118, 2004-2013.	2.0	43
88	Estrogen-related receptor alpha: an orphan finds a family. <i>Breast Cancer Research</i> , 2012, 14, 309.	2.2	6
89	Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine. <i>AAPS Journal</i> , 2012, 14, 1-9.	2.2	11
90	Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 251-261.	1.0	78

#	ARTICLE	IF	CITATIONS
91	The Influence of Therapeutic Radiation on the Patterns of Bone Marrow in Ovary-Intact and Ovariectomized Mice. PLoS ONE, 2012, 7, e42668.	1.1	26
92	Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type IIGF receptor. Breast Cancer Research and Treatment, 2012, 133, 117-126.	1.1	28
93	Skeletal Remodeling Following Clinically Relevant Radiation-Induced Bone Damage Treated with Zoledronic Acid. Calcified Tissue International, 2012, 90, 40-49.	1.5	10
94	IGF System and Breast Cancer. , 2012, , 73-84.		0
95	Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives. Expert Opinion on Medical Diagnostics, 2011, 5, 241-251.	1.6	20
96	Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocrine-Related Cancer, 2011, 18, C19-C24.	1.6	117
97	The IGF Pathway Regulates ER $\alpha$ through a S6K1-Dependent Mechanism in Breast Cancer Cells. Molecular Endocrinology, 2011, 25, 516-528.	3.7	99
98	Targeting IGF-1R: at a crossroad. Oncology, 2011, 25, 535-6; discussion 551.	0.4	13
99	MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer. Hormones and Cancer, 2010, 1, 306-319.	4.9	115
100	Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Research and Treatment, 2010, 122, 585-590.	1.1	32
101	Diabetes and Cancer: A Consensus Report. Ca-A Cancer Journal for Clinicians, 2010, 60, 207-221.	157.7	724
102	Longitudinal assessment of bone loss from diagnostic computed tomography scans in gynecologic cancer patients treated with chemotherapy and radiation. American Journal of Obstetrics and Gynecology, 2010, 203, 353.e1-353.e7.	0.7	28
103	The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene, 2010, 29, 251-262.	2.6	85
104	Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene, 2010, 29, 2517-2527.	2.6	111
105	How to Train Your Biomarker. Clinical Cancer Research, 2010, 16, 3091-3093.	3.2	2
106	Adaptor Proteins as Targets for Cancer Prevention. Cancer Prevention Research, 2010, 3, 263-265.	0.7	4
107	Diabetes and Cancer. Diabetes Care, 2010, 33, 1674-1685.	4.3	1,618
108	Basic Principles of Antineoplastic Therapies. , 2010, , 707-715.		0

#	ARTICLE	IF	CITATIONS
109	Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response <i>in vitro</i> and <i>in vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 2840-2849.	3.2	33
110	Metabolite quantification and high-field MRS in breast cancer. <i>NMR in Biomedicine</i> , 2009, 22, 65-76.	1.6	137
111	Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 277-285.	1.1	41
112	Fluorescent tumour imaging of type I IGF receptor <i>in vivo</i> : comparison of antibody-conjugated quantum dots and small-molecule fluorophore. <i>British Journal of Cancer</i> , 2009, 101, 71-79.	2.9	50
113	Targeting the insulin-like growth factor receptor. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 452-4.	0.3	1
114	The IGF System in Mammary Development and Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 351-352.	1.0	7
115	Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 423-429.	1.0	149
116	Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. <i>Nanomedicine</i> , 2008, 3, 83-91.	1.7	212
117	Progesterone and Breast Cancer. <i>Women's Health</i> , 2008, 4, 151-162.	0.7	64
118	Progesterone Receptor-B Regulation of Insulin-Like Growth Factor-Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2. <i>Molecular Cancer Research</i> , 2008, 6, 1491-1498.	1.5	21
119	Of Mice and (Wo)Men: Is This Any Way to Test a New Drug?. <i>Journal of Clinical Oncology</i> , 2008, 26, 830-832.	0.8	17
120	Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) Receptors. , 2008, , 147-160.		1
121	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. <i>Journal of Clinical Investigation</i> , 2008, 118, 2609-19.	3.9	443
122	Hawai'i's role to increase public participation in health research. <i>Hawaii Medical Journal</i> , 2008, 67, 4-6.	0.4	1
123	Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin. <i>Cancer Research</i> , 2007, 67, 391-397.	0.4	138
124	Insulin-Like Growth Factor (IGF)-I Controls Prostate Fibromuscular Development: IGF-I Inhibition Prevents Both Fibromuscular and Glandular Development in Eugonadal Mice. <i>Endocrinology</i> , 2007, 148, 1080-1088.	1.4	21
125	Disrupting insulin-like growth factor signaling as a potential cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1-12.	1.9	339
126	Short versus continuous gemcitabine treatment of non-small cell lung cancer in an <i>in vitro</i> cell culture bioreactor system. <i>Lung Cancer</i> , 2007, 58, 196-204.	0.9	6



#	ARTICLE	IF	CITATIONS
127	Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 291-299.	1.1	17
128	Insulin-Like Growth Factors and Breast Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 101-112.	0.8	25
129	Effects of Insulin-Like Growth Factor-1 Receptor Inhibition in Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2006, 82, 996-1002.	0.7	19
130	Targeting insulin-like growth factor pathways. <i>British Journal of Cancer</i> , 2006, 94, 465-468.	2.9	100
131	Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 27-39.	1.0	55
132	Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 217-225.	1.1	14
133	Effects of weight training on quality of life in recent breast cancer survivors. <i>Cancer</i> , 2006, 106, 2076-2083.	2.0	179
134	Targeting the insulin-like growth factor axis as a cancer therapy. <i>Future Oncology</i> , 2006, 2, 101-110.	1.1	10
135	Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti-Insulin-Like Growth Factor Therapy in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 2391-2402.	0.4	110
136	Randomized Controlled Trial of Weight Training and Lymphedema in Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2006, 24, 2765-2772.	0.8	276
137	Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 611-620.	1.9	53
138	Is the Type I Insulin-Like Growth Factor Receptor a Therapeutic Target in Endometrial Cancer?: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6323-6325.	3.2	13
139	Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. <i>British Journal of Cancer</i> , 2006, 95, 1220-1228.	2.9	109
140	Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 159-168.	1.1	63
141	Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer: Figure 1.. <i>Cancer Research</i> , 2005, 65, 10123-10127.	0.4	100
142	Adding in Vivo Quantitative <sup>1</sup> H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T. <i>Radiology</i> , 2005, 236, 465-475.	3.6	135
143	Safety and Efficacy of Weight Training in Recent Breast Cancer Survivors to Alter Body Composition, Insulin, and Insulin-Like Growth Factor Axis Proteins. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1672-1680.	1.1	269
144	Imaging in breast cancer: Magnetic resonance spectroscopy. <i>Breast Cancer Research</i> , 2005, 7, 149-52.	2.2	100

#	ARTICLE	IF	CITATIONS
145	Insulin-like growth factor-I and breast cancer therapy. <i>Clinical Cancer Research</i> , 2005, 11, 944s-50s.	3.2	30
146	Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo <sup>1</sup> H MR Spectroscopy—A Pilot Study at 4 T. <i>Radiology</i> , 2004, 233, 424-431.	3.6	304
147	A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 5017-5024.	1.6	142
148	Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells. <i>Cancer Research</i> , 2004, 64, 7479-7485.	0.4	67
149	Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. <i>Cancer Cell</i> , 2004, 5, 553-563.	7.7	318
150	Motility Response to Insulin-like Growth Factor-I (IGF-I) in MCF-7 Cells is Associated with IRS-2 Activation and Integrin Expression. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 161-170.	1.1	48
151	The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1569-1577.	1.9	65
152	Insulin-like growth factor-I and cancer risk. <i>Growth Hormone and IGF Research</i> , 2004, 14, 261-269.	0.5	95
153	The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. <i>Cancer and Metastasis Reviews</i> , 2003, 22, 327-336.	2.7	44
154	Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 125-132.	0.8	17
155	In vivo quantification of choline compounds in the breast with <sup>1</sup> H MR spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 1134-1143.	1.9	317
156	The $\alpha 2$ and $\alpha 3$ integrins are required for morphologic differentiation of an intestinal epithelial cell line. <i>Surgery</i> , 2003, 133, 429-437.	1.0	21
157	Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13988-13993.	3.3	68
158	The Type I IGF Receptor as a Target for Breast Cancer Therapy. <i>Breast Disease</i> , 2003, 17, 115-124.	0.4	2
159	A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. <i>Cancer Research</i> , 2003, 63, 627-35.	0.4	147
160	Cyclin E in breast cancer. <i>New England Journal of Medicine</i> , 2003, 348, 1063-4; author reply 1063-4.	13.9	0
161	Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. <i>Clinical Cancer Research</i> , 2003, 9, 2440-6.	3.2	70
162	Breast disease. Introduction. <i>Breast Disease</i> , 2003, 17, 1-2.	0.4	0

#	ARTICLE	IF	CITATIONS
163	How does the estrogen receptor work?. Breast Cancer Research, 2002, 4, 62-4.	2.2	33
164	STAT6 Mediates Interleukin-4 Growth Inhibition in Human Breast Cancer Cells. Neoplasia, 2002, 4, 324-331.	2.3	72
165	The insulin-like growth factor system as a treatment target in breast cancer. Seminars in Oncology, 2002, 29, 86-95.	0.8	16
166	Eliminating spurious lipid sidebands in 1H MRS of breast lesions. Magnetic Resonance in Medicine, 2002, 48, 215-222.	1.9	97
167	The insulin-like growth factor system as a treatment target in breast cancer. Seminars in Oncology, 2002, 29, 86-95.	0.8	32
168	Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Research, 2002, 62, 4369-75.	0.4	54
169	Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1597-604.	1.1	23
170	Are the insulin-like growth factors relevant to cancer?. Growth Hormone and IGF Research, 2001, 11, 339-345.	0.5	15
171	EGF receptor: new trick for an old dog?. Breast Cancer Research, 2001, 3, 1.	2.2	0
172	Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene, 2001, 20, 7318-7325.	2.6	118
173	Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions. Journal of Biological Chemistry, 2001, 276, 27907-27912.	1.6	144
174	The IGF system and breast cancer.. Endocrine-Related Cancer, 2001, 8, 197-209.	1.6	267
175	Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene, 2000, 19, 4574-4581.	2.6	83
176	Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells. Breast Cancer Research and Treatment, 2000, 62, 109-115.	1.1	4
177	Crosstalk between the insulin-like growth factors and estrogens in breast cancer. , 2000, 5, 107-115.		210
178	Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer. , 2000, 5, 1-5.		26
179	Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3 $\alpha$ -Kinase Inhibition. Molecular and Cellular Biology, 2000, 20, 1489-1496.	1.1	113
180	Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer. Breast Cancer Research, 2000, 2, 170-5.	2.2	75

#	ARTICLE	IF	CITATIONS
181	Insulin-Like Growth Factors and Endocrine Neoplasia. , 2000, , 193-214.		0
182	FKHR Binds the Insulin Response Element in the Insulin-Like Growth Factor Binding Protein-1 Promoter*. Endocrinology, 1999, 140, 3140-3146.	1.4	145
183	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. Molecular Endocrinology, 1999, 13, 787-796.	3.7	292
184	Insulin-like growth factor (IGF) rescues breast cancer cells from chemotherapy-induced cell death – proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment, 1999, 56, 1-10.	1.1	174
185	IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. Growth Hormone and IGF Research, 1999, 9, 280-289.	0.5	18
186	Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Letters, 1999, 144, 31-37.	3.2	65
187	Igf system components as prognostic markers in breast cancer. Breast Cancer Research and Treatment, 1998, 47, 295-302.	1.1	70
188	The insulin-like growth factors and breast cancer – revisited. Breast Cancer Research and Treatment, 1998, 47, 197-199.	1.1	33
189	Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells. Journal of Biological Chemistry, 1998, 273, 9994-10003.	1.6	147
190	Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. British Journal of Cancer, 1998, 77, 2138-2147.	2.9	30
191	Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10 <sup>3</sup> .. Journal of Biological Chemistry, 1998, 273, 4288.	1.6	0
192	Cloning, Chromosome Localization, Expression, and Characterization of an Src Homology 2 and Pleckstrin Homology Domain-containing Insulin Receptor Binding Protein hGrb10 <sup>3</sup> . Journal of Biological Chemistry, 1997, 272, 29104-29112.	1.6	69
193	Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. Journal of Endocrinology, 1997, 152, 39-47.	1.2	169
194	Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice. Biomedicine and Pharmacotherapy, 1996, 50, 154-157.	2.5	10
195	Characterization of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells. Kidney International, 1996, 49, 1071-1078.	2.6	22
196	Correlation of Insulin-Like Growth Factor-Binding Protein-3 Messenger RNA With Protein Expression in Primary Breast Cancer Tissues: Detection of Higher Levels in Tumors With Poor Prognostic Features. Journal of the National Cancer Institute, 1996, 88, 601-606.	3.0	97
197	Interaction between insulin-like growth factor-I and insulin-like growth factor-binding proteins in TC-1 stromal cells. Journal of Endocrinology, 1996, 149, 519-529.	1.2	7
198	Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast Cancer. Human Gene Therapy, 1996, 7, 1251-1257.	1.4	54

#	ARTICLE	IF	CITATIONS
199	Characterization of Insulin-Like Growth Factor and Its Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells. <i>Journal of Neurochemistry</i> , 1996, 66, 525-536.	2.1	102
200	Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP in bone marrow stromal cells. <i>British Journal of Haematology</i> , 1995, 90, 249-257.	1.2	22
201	Insulin-like growth factors and breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 1995, 49, 415-421.	2.5	85
202	The insulin-like growth factor system as a target in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 85-95.	1.1	55
203	Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. <i>Cancer Letters</i> , 1994, 77, 25-32.	3.2	37
204	Use of Insulin-like Growth Factor-I Gene Expression to Distinguish Between Breast and Ovarian Cancer. <i>American Journal of the Medical Sciences</i> , 1994, 307, 108-111.	0.4	2
205	Insulin-like growth factor binding proteins: Potential inhibitors of cancer cell growth. <i>Drugs of the Future</i> , 1994, 19, 477.	0.0	2
206	Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. <i>Journal of Cellular Biochemistry</i> , 1993, 52, 196-205.	1.2	90
207	Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. <i>Journal of Cellular Physiology</i> , 1993, 157, 229-236.	2.0	75
208	Phase II trial of 13-cis-retinoic acid plus interferon- $\alpha$ in recurrent head and neck cancer. <i>Investigational New Drugs</i> , 1993, 11, 57-60.	1.2	23
209	Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. <i>European Journal of Cancer</i> , 1993, 29, 2015-2019.	1.3	31
210	Insulin-like Growth Factor Binding Protein Expression in SH-SY5Y Neuroblastoma Cells. <i>Annals of the New York Academy of Sciences</i> , 1993, 692, 262-264.	1.8	1
211	Insulin-like Growth Factor Binding Protein Expression in Human Retinal Pigment Epithelial Cells. <i>Annals of the New York Academy of Sciences</i> , 1993, 692, 265-267.	1.8	8
212	Prognostic Indicators in Early Breast Cancer. <i>American Journal of the Medical Sciences</i> , 1993, 305, 176-182.	0.4	24
213	In vitro Sensitivity Testing of Human Bladder Cancers and Cell Lines to TP-40, a Hybrid Protein with selective Targeting and Cytotoxicity. <i>Journal of Urology</i> , 1993, 150, 1950-1955.	0.2	11
214	Regulation of Insulin-Like Growth Factor-Binding Protein (IGFBP) Expression by Breast Cancer Cells: Use of IGFBP-1 as as Inhibitor of Insulin-like Growth Factor Action. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1336-1341.	3.0	104
215	Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. <i>Molecular Brain Research</i> , 1992, 12, 181-186.	2.5	57
216	Can the insulin-like growth factors regulate breast cancer growth?. <i>Breast Cancer Research and Treatment</i> , 1992, 22, 3-5.	1.1	9

#	ARTICLE	IF	CITATIONS
217	The insulin-like growth factor family of ligands, receptors, and binding proteins. <i>Breast Cancer Research and Treatment</i> , 1992, 22, 7-19.	1.1	54
218	The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1992, 22, 81-90.	1.1	46
219	Insulinlike Growth Factors in Human Malignancy. <i>Cancer Investigation</i> , 1991, 9, 443-454.	0.6	45
220	Identification of insulin-like growth factor binding proteins in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 1991, 18, 3-10.	1.1	68
221	Insulin-like growth factors in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1991, 18, S55-S62.	1.1	56
222	A Novel Human Insulin-Like Growth Factor I Messenger RNA is Expressed in Normal and Tumor Cells. <i>Molecular Endocrinology</i> , 1990, 4, 1914-1920.	3.7	57
223	Analysis of Insulin-Like Growth Factor I Gene Expression in Malignancy: Evidence for a Paracrine Role in Human Breast Cancer. <i>Molecular Endocrinology</i> , 1989, 3, 509-517.	3.7	387
224	FKHR Binds the Insulin Response Element in the Insulin-Like Growth Factor Binding Protein-1 Promoter. , 0, .		59